Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Vertex Pharmaceuticals’ CRISPR-based therapy made history as ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...

Vertex Pharmaceuticals (VRTX) shares saw mild movement today, with the stock ticking slightly higher over the past week. Investors seem to be watching recent performance rather than reacting to fresh ...

Vertex Pharmaceuticals' leading cystic fibrosis franchise still looks promising. It also has a couple of exciting newer launches, and could land another one. Shares of the large drugmaker could still ...

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the ...